Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.32
25.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Diffusion Pharmaceuticals Inc
Net Issuance of Common Stock
Diffusion Pharmaceuticals Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
|
Net Issuance of Common Stock
$46.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
52%
|
CAGR 10-Years
4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Common Stock
-$782m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Common Stock
-$243.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Diffusion Pharmaceuticals Inc
Glance View
Diffusion Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2016-11-09. Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed. The Company’s product candidate, Trans Sodium Crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The firm is focused on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia with a particular near-term focus on hypoxic solid tumors. Hypoxia is associated with the pathophysiology of many acute and chronic conditions including cancers, heart attack, stroke, ARDS, skin and soft tissue diseases, neurodegenerative diseases and other intractable and difficult-to-treat conditions, further complicating treatment of the underlying condition by medical providers.
See Also
What is Diffusion Pharmaceuticals Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
46.4m
USD
Based on the financial report for Sep 30, 2024, Diffusion Pharmaceuticals Inc's Net Issuance of Common Stock amounts to 46.4m USD.
What is Diffusion Pharmaceuticals Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
4%
Over the last year, the Net Issuance of Common Stock growth was 5 628%. The average annual Net Issuance of Common Stock growth rates for Diffusion Pharmaceuticals Inc have been 12% over the past three years , 52% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet
